Stereotactic Body Radiotherapy for Metachronous Multisite Oligo-Recurrence: A Long-Surviving Case with Sequential Oligo-Recurrence in Four Different Organs Treated Using Locally Radical Radiotherapy and a Review of the Literature

Table 1

Studies of stereotactic body radiotherapy for pulmonary oligometastases.

Authors	Study design	Number of patients	Number of metastases in each patient	Primary organ	Dose/fractionation	Followup (months)	Outcomes	Toxicity
Okunieff et al. [20]	Retrospective	42	1 to 5	NA	50 Gy/5 fr; (isocenter)	4–61 (median 15)	Crude LC: 94%; MS: 23.4 months	Grade 3 (pleural effusion): 1
Kavanagh et al. [36]	Retrospective	34	1 or 2	Lung 15, Colorectal: 9; Others 10	48–60 Gy/4-5 fr; (isocenter)	10–80 (median, 27)	2-year LC: 90%; 2-year OS: 84.3%	Grade 3 pneumonitis: 3
Nagata et al. [37]	Retrospective	84	1 to 3	Lung 32, Colorectal 11,; Kidney 7, others 34	26–48 Gy/1–8 fr; (covering PTV)	14–80 (median, 17)	3-year LC: 82%; 3-year OS: 16%	NA
Norihisa et al. [38]	Prospective	41	1 or 2	Lung 5, Breast 4,; Kidney 4, Others 14	26–37.5 Gy/1–3 fr	2–37 (median, 9)	2-year LC: 80%; 2-year OS: 33%	No grade 3, 4
Ernst-Stecken et al. [42]	Prospective	61	1 or 2	Lung 31, Colorectal 8,; Others 22	12–30 Gy/fr; (isocenter)	2–82 (median, 14)	2-year LC: 74%; 2-year OS: 65%	Grade 3 pneumonitis: 3%
Hof et al. [44]	Prospective	38	1 to 3	Colorectal 9, Sarcoma 7,; Kidney 7, others 15	48–60 Gy/3 fr; (covering PTV)	6–48 (median, 16)	2-year LC: 96%; MS: 19 months	Grade 3 pneumonitis: 4; Grade 3 chest wall: 2

Abbreviations: NA: not available; LC: local control rate; OS: overall survival rate; LPFS: locally progression-free survival rate.